Moshe Yanai

Angel investor in Boston

Invests in AI

Moshe Yanai's investor profile lists AI alongside Fintech, Healthcare & Biotech and Biotech & Pharma, at pre-seed, seed and non-equity support. The record holds 4 deals, among them Sight Diagnostics, Infinidat and Axxana.

Email Investor

Email Investor

Credits to line up before a pre-seed round

Moshe Yanai backs companies at pre-seed, seed and non-equity support. A few of the larger credit programs on AI Perks for teams at that point:

Portfolio on record

Portfolio companies

  • Sight Diagnostics
  • Infinidat
  • Axxana
  • Quris

Investment focus

Backs startups in
Artificial Intelligence, Fintech, Healthcare & Biotech, Biotech & Pharma, SaaS & Enterprise, Consumer & Retail and 13 more
Rounds
Pre-seed, Seed, Non-equity support
Profile
Angel investor
Deals on record
4
Based in
Boston, United States

Ready to pitch AI investors?

AI Perks profiles show public professional information only, so there are no contact details here. Continue to find investors, send your pitch and track the replies.

Email Investor

Email Investor

More AI investors on AI Perks

Browse all AI investors

Questions founders ask

Does Moshe Yanai invest in AI startups?
Yes. Artificial Intelligence is one of the sectors on Moshe Yanai's investor profile, together with Fintech, Healthcare & Biotech and Biotech & Pharma. The stages on record are pre-seed, seed and non-equity support.
Which companies has Moshe Yanai backed?
The record lists 4 deals, including Sight Diagnostics, Infinidat, Axxana and Quris. None of them has a perk listed on AI Perks yet.
What credits can a startup claim before pitching Moshe Yanai?
For a company raising a pre-seed round, AI Perks lists credits such as Algolia (up to $10,000), Oracle (up to $10,000), Redis (up to $10,000) and Mistral AI (up to $10,000), with each program's terms and how to apply.
Does AI Perks publish investor contact details?
No. AI Perks profiles show public professional information only: name, role, location, stages, sectors and the portfolio on record. To reach investors, continue with the Email Investor button below.Email Investor

Email Investor

Source: public professional information. Is this you? Request removal

Email Investor

Email Investor